Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 5/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26913112 | 0.87 | CA1 (0.40) | CA1CA2BRD4RAPGEF4L3MBTL1 | |
| SCHEMBL26912429 | 0.86 | HTR6 (0.43) | ALDH1A1HTTHTR6 | |
| SCHEMBL26912221 | 0.84 | BRD4 (0.40) | CA1CA2BRD4RAPGEF4L3MBTL1 | |
| SCHEMBL26913270 | 0.79 | PPARG (0.43) | BRD4RAPGEF4ALDH1A1HTTMAPT | |
| SCHEMBL26912802 | 0.78 | BRD4 (0.37) | CA1CA2BRD4RAPGEF4L3MBTL1 | |
| SCHEMBL2128761 | 0.78 | ABL1 (0.45) | CA1CA2BRD4RAPGEF4L3MBTL1 | |
| SCHEMBL26912170 | 0.77 | CA1 (0.43) | CA1CA2BRD4RAPGEF4L3MBTL1 | |
| SCHEMBL30946451 | 0.77 | BRD4 (0.39) | CA1CA2BRD4RAPGEF4L3MBTL1 | |
| SCHEMBL26913079 | 0.77 | BRD4 (0.36) | BRD4RAPGEF4L3MBTL1ALDH1A1HTT | |
| SCHEMBL26912212 | 0.77 | MEN1 (0.40) | BRD4RAPGEF4L3MBTL1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | CA1 2865/4885CA2 985/4885BRD4 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.